We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sorrento Therapeutics (SRNE) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Sorrento Therapeutics (SRNE - Free Report) closed at $7.03 in the latest trading session, marking a -0.57% move from the prior day. This move lagged the S&P 500's daily gain of 0.57%. At the same time, the Dow added 1.44%, and the tech-heavy Nasdaq lost 0.61%.
Coming into today, shares of the biopharmaceutical company had lost 10.51% in the past month. In that same time, the Medical sector lost 0.91%, while the S&P 500 gained 0.83%.
Wall Street will be looking for positivity from SRNE as it approaches its next earnings report date. On that day, SRNE is projected to report earnings of $5.79 per share, which would represent year-over-year growth of 1512.2%. Meanwhile, our latest consensus estimate is calling for revenue of $2.02 billion, up 15404.99% from the prior-year quarter.
Any recent changes to analyst estimates for SRNE should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. SRNE is currently a Zacks Rank #3 (Hold).
Investors should also note SRNE's current valuation metrics, including its Forward P/E ratio of 2.05. This represents a discount compared to its industry's average Forward P/E of 23.45.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 198, putting it in the bottom 23% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow SRNE in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sorrento Therapeutics (SRNE) Stock Sinks As Market Gains: What You Should Know
Sorrento Therapeutics (SRNE - Free Report) closed at $7.03 in the latest trading session, marking a -0.57% move from the prior day. This move lagged the S&P 500's daily gain of 0.57%. At the same time, the Dow added 1.44%, and the tech-heavy Nasdaq lost 0.61%.
Coming into today, shares of the biopharmaceutical company had lost 10.51% in the past month. In that same time, the Medical sector lost 0.91%, while the S&P 500 gained 0.83%.
Wall Street will be looking for positivity from SRNE as it approaches its next earnings report date. On that day, SRNE is projected to report earnings of $5.79 per share, which would represent year-over-year growth of 1512.2%. Meanwhile, our latest consensus estimate is calling for revenue of $2.02 billion, up 15404.99% from the prior-year quarter.
Any recent changes to analyst estimates for SRNE should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. SRNE is currently a Zacks Rank #3 (Hold).
Investors should also note SRNE's current valuation metrics, including its Forward P/E ratio of 2.05. This represents a discount compared to its industry's average Forward P/E of 23.45.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 198, putting it in the bottom 23% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow SRNE in the coming trading sessions, be sure to utilize Zacks.com.